<DOC>
	<DOCNO>NCT01039480</DOCNO>
	<brief_summary>Resistance antiplatelet drug ( aspirin , clopidogrel ) recognize phenomenon prevalence 17 % 35 % . Resistance detect vitro test Multiple Electrode Aggregometry ( MEA ) show predict clinical therapy failure . Resistance cause clinical , cellular pharmacogenetic factor . Non compliance suspect important contributing factor . In study , compliance assure electronical compliance monitoring system . Factors non response identify find plausible explanation vitro platelet aggregation inhibition insufficient despite assured compliance . This study help disclose relationship compliance , biomarker clinical outcome well quantify impact non compliance resistance phenomenon measure MEA .</brief_summary>
	<brief_title>Aspirin Clopidogrel Resistance Study</brief_title>
	<detailed_description />
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<criteria>Patients prescribe aspirin and/or clopidogrel include cardiovascular cerebrovascular indication see general practitioner nearby Olten/SO medical purpose Patients oral write German language ability Patients live care home Patients prepare drug ( e.g . outpatient medical assistance `` spitex '' ) . Patients acute cardiac symptom</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>pharmacological biomarker</keyword>
	<keyword>compliance monitoring</keyword>
	<keyword>platelet aggregometry</keyword>
	<keyword>resistance</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Medication Non-Compliance</keyword>
</DOC>